Keywords: MAP Thera, Levadex, Migraine, USA, FDA, Market forecast, Allergan

FDA delay for MAP Pharma migraine drug candidate

Article | 28 March 2012

Print This

Shares of USA-based MAP Pharmaceuticals (Nasdaq: MAPP) plunged 24% to $13.01 in early trading yesterday, after the firm said it has received ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in